Editas Medicine, Inc. (EDIT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration and other research and development revenues | 3,578 | 4,658 | 61 | 513 |
| Restructuring and impairment charges | 26,082 | 40,853 | - | - |
| Research and development | 16,181 | 26,593 | 47,639 | 54,210 |
| General and administrative | 12,859 | 13,375 | 18,088 | 18,206 |
| Total operating expenses | 55,122 | 80,821 | 65,727 | 72,416 |
| Operating loss | -51,544 | -76,163 | -65,666 | -71,903 |
| Other (expense) income, net | -1,758 | -425 | -5 | -1 |
| Interest income, net | 2,087 | 2,716 | 3,530 | 4,297 |
| Interest related to sale of future revenues | 2,020 | 2,216 | - | - |
| Total other (expense) income, net | -1,691 | 75 | 3,525 | 4,296 |
| Net loss | -53,235 | -76,088 | -62,141 | -67,607 |
| Net loss per share, basic (in dollars per share) | -0.63 | -0.92 | -0.75 | -0.82 |
| Net loss per share, diluted (in dollars per share) | -0.63 | -0.92 | -0.75 | -0.82 |
| Weighted-average common shares outstanding, basic (in shares) | 84,412,200 | 83,055,066 | 82,485,199 | 82,310,368 |
| Weighted-average common shares outstanding, diluted (in shares) | 84,412,200 | 83,055,066 | 82,485,199 | 82,310,368 |